JP2012524796A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524796A5
JP2012524796A5 JP2012507354A JP2012507354A JP2012524796A5 JP 2012524796 A5 JP2012524796 A5 JP 2012524796A5 JP 2012507354 A JP2012507354 A JP 2012507354A JP 2012507354 A JP2012507354 A JP 2012507354A JP 2012524796 A5 JP2012524796 A5 JP 2012524796A5
Authority
JP
Japan
Prior art keywords
compound according
compound
following formula
optionally substituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012507354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524796A (ja
JP5734957B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/031916 external-priority patent/WO2010124005A1/en
Publication of JP2012524796A publication Critical patent/JP2012524796A/ja
Publication of JP2012524796A5 publication Critical patent/JP2012524796A5/ja
Application granted granted Critical
Publication of JP5734957B2 publication Critical patent/JP5734957B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012507354A 2009-04-21 2010-04-21 ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用 Expired - Fee Related JP5734957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17127309P 2009-04-21 2009-04-21
US61/171,273 2009-04-21
PCT/US2010/031916 WO2010124005A1 (en) 2009-04-21 2010-04-21 Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor

Publications (3)

Publication Number Publication Date
JP2012524796A JP2012524796A (ja) 2012-10-18
JP2012524796A5 true JP2012524796A5 (https=) 2013-06-06
JP5734957B2 JP5734957B2 (ja) 2015-06-17

Family

ID=43011462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507354A Expired - Fee Related JP5734957B2 (ja) 2009-04-21 2010-04-21 ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用

Country Status (4)

Country Link
US (1) US9359303B2 (https=)
EP (1) EP2421862B1 (https=)
JP (1) JP5734957B2 (https=)
WO (1) WO2010124005A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011301B (zh) * 2017-05-27 2019-06-28 山东省联合农药工业有限公司 一种2-(2-甲氧基苯基)-5-氧代四氢呋喃-3-羧酸的制备方法
CA3148598A1 (en) 2019-07-30 2021-02-04 Mayo Foundation For Medical Education And Research Compounds and methods for treating fibrotic pathologies
US20240043396A1 (en) * 2021-01-29 2024-02-08 Mayo Foundation For Medical Education And Research Methods of treating ocular fibrotic pathologies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912740A (en) 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
DK297275A (da) 1974-08-07 1976-02-08 Aspro Nicholas Ltd Isoquinolinderivater
US3939165A (en) 1974-11-14 1976-02-17 Morton-Norwich Products, Inc. 5,6,6A,6B,7,8-Hexahydrobenz[a]phenanthridine hydrochloride
US4346090A (en) 1977-07-21 1982-08-24 Ayerst, Mckenna & Harrison Ltd. 13-Chloro-benzocycloheptapyridoisoquinolines and use as neuroleptics
CA1270253A (en) 1981-06-18 1990-06-12 John L. Neumeyer R(-)-10,11-alkylenedioxy-n-alkylnorapomorphine
US4678791A (en) * 1985-05-07 1987-07-07 Pennwalt Corporation 6-phenyl-1,2-3,4,4a,5-6,10b-octahydrobenz(h)isoquinolines useful for treating depression
US4737503A (en) 1986-10-08 1988-04-12 Vipont Laboratories, Inc. Method for inhibiting the release of histamine
US5047536A (en) 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) * 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
GB8917333D0 (en) 1989-07-28 1989-09-13 Merck Sharp & Dohme Therapeutic agents
US5180733A (en) 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5635506A (en) 1990-06-26 1997-06-03 Research Corporation Technologies, Inc. 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
US5266702A (en) 1990-09-19 1993-11-30 Council Of Scientific & Industrial Research 1,3-oxazoline compounds useful as anionic initiators suitable for polymerization of vinyl polymers
US5216018A (en) 1992-02-14 1993-06-01 Du Pont Merck Pharmaceutical Company Hydroisoindolines and hydroisoquinolines as psychotropic
WO1993024462A1 (en) 1992-05-26 1993-12-09 Purdue Research Foundation Substituted-hexahydrobenzo[a]phenanthridines
US5438131A (en) 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
FI954738A7 (fi) 1993-04-06 1995-12-05 Abbott Lab Tetrasykliini yhdisteet dopamiiniagonisteina
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
WO1996038435A1 (en) 1995-05-30 1996-12-05 Abbott Laboratories Dopamine agonists
US5554621A (en) * 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
MX9801179A (es) 1995-08-18 1998-04-30 Purdue Research Foundation Isoquinolinas fusionadas, novedosas como ligandos del receptor de dopamina.
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU4536599A (en) 1999-06-21 2001-01-09 Geochemistry Research Limited Metal-rich silica products from geothermal and synthetic aqueous systems nen wie
US6733797B1 (en) 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
WO2002056875A2 (en) 2001-01-16 2002-07-25 Purdue Research Foundation Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
DE60323339D1 (de) 2002-02-15 2008-10-16 Darpharma Inc Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten
EP1699450A4 (en) 2003-12-23 2009-11-11 Darpharma Inc Simultaneous administration of dopamine receptor bindings
US20070254906A1 (en) 2004-07-21 2007-11-01 Darpharma, Inc. Method of Administration of Dopamine Receptor Agonists
US7563805B2 (en) 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
PE20070549A1 (es) 2005-10-17 2007-06-15 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
NZ570606A (en) 2006-02-21 2011-11-25 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use

Similar Documents

Publication Publication Date Title
JP2009143956A5 (https=)
JP2009542613A5 (https=)
WO2012138894A4 (en) Hsp90 inhibitors
JP2012512907A5 (https=)
JP2015501820A5 (https=)
CN1575287A (zh) 乙酰替苯胺衍生物的α型或β型结晶
JP2012515142A5 (https=)
JP2009120598A5 (https=)
JP2013510120A5 (https=)
JP2012513416A5 (https=)
JP2013541592A5 (https=)
JP2012519182A5 (https=)
JP2015508092A5 (https=)
JP2005500355A5 (https=)
JP2011523952A5 (https=)
JP2014528948A5 (https=)
JP2012144537A5 (https=)
JP2012509265A5 (https=)
JP2012524796A5 (https=)
JP2013515037A5 (https=)
CN101039917A (zh) 制备替米沙坦的方法
JP2017522304A5 (https=)
JP2013537240A5 (https=)
JP2013520488A5 (https=)
JP2015502973A5 (https=)